Patents by Inventor David J. Morgan

David J. Morgan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds, compositions and methods
    Patent number: 10035770
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: July 31, 2018
    Assignee: Cytokinetics, Incorporated
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20170267638
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: April 6, 2017
    Publication date: September 21, 2017
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.
  • Compounds, compositions and methods
    Patent number: 9643925
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: May 9, 2017
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20160115133
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: August 27, 2015
    Publication date: April 28, 2016
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.
  • Multi-magnification high sensitivity optical system for probing electronic devices
    Patent number: 9217855
    Abstract: An optical probe system for probing an electronic device includes a sample plate configured to hold a target device comprising an integrated circuit, a temperature control chamber configured to hold a fluid to control the temperature of the target device, a first optical objective system that can collect reflected or emitted light from the integrated circuit in the target device, a rotational stage including ports that can hold the optical objective systems, a vertical translation stage that can move the first optical objective system in a vertical direction substantially perpendicular to the sample plate, and an x-y translation stage that can move the first optical objective system in horizontal directions. A portion of the first optical objective system is moved through the temperature control chamber to allow the first optical objective system to focus at the target device.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: December 22, 2015
    Assignee: CheckPoint Technologies, LLC
    Inventors: Thomas E Clawges, David J Morgan, Guoqing Xiao
  • Optical probe system having accurate positional and orientational adjustments for multiple optical objectives
    Patent number: 9182580
    Abstract: An optical probe system includes a sample plate for holding a target device comprising an integrated circuit, and a rotational stage that includes a plurality of ports configured to receive and hold a plurality of optical objective systems that can collect reflected or emitted light from the integrated circuit. At least one of the ports includes a centering plate mounted on the rotational stage and configured to conduct a translational movement on the rotational stage. The port also includes a gimbal plate mounted on the centering plate and that can be tilted relative to the centering plate. A first optical objective system that is mounted on the gimbal plate can be centered by the center plate and aligned by the gimbal plate.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: November 10, 2015
    Assignee: CheckPoint Technologies, LLC
    Inventors: Thomas E Clawges, David J Morgan, Guoqing Xiao
  • Compounds, compositions and methods
    Patent number: 9150564
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: October 6, 2015
    Assignee: CYTOKINETICS, INC.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Multi-resolution optical probing system having reliable temperature control and mechanical isolation
    Patent number: 9030658
    Abstract: An optical probe system for probing an electronic device includes a sample plate that can hold a target device comprising an integrated circuit, an optical objective system that can collect reflected or emitted light from the integrated circuit in the target device, and a temperature control chamber that can hold a fluid to control the temperature of the target device.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: May 12, 2015
    Assignee: CheckPoint Technologies, LLC
    Inventors: David J Morgan, Thomas E Clawges, Horst E Groneberg, Guoqing Xiao
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20150005296
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.
  • Certain chemical entities, compositions, and methods
    Patent number: 8895582
    Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: November 25, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Xiangping Qian, Chihyuan (Grace) Chuang, Pu-Ping Lu, Bing Yao, Qing (Kevin) Lu, Hong Jiang, Wenyue Wang, Bradley P. Morgan, David J. Morgans, Jr.
  • Ureas and their use in the treatment of heart failure
    Patent number: 8871769
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: October 28, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans
  • Optical probing system having reliable temperature control
    Patent number: 8873032
    Abstract: An optical probe system for probing an electronic device includes a sample plate that can hold a target device comprising an integrated circuit, an optical objective system that can collect reflected or emitted light from the integrated circuit in the target device, and a temperature control chamber that can hold a fluid to control the temperature of the target device.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: October 28, 2014
    Assignee: CheckPoint Technologies, LLC.
    Inventors: David J Morgan, Thomas E Clawges, Horst E Groneberg, Guoqing Xiao
  • Certain chemical entities, compositions and methods
    Patent number: 8871768
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: October 28, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley P. Morgan, David J. Morgans, Alex Muci, Pu-Ping Lu, Erica A. Kraynack, Todd Tochimoto
  • Imidazole-benzamide anti-cancer agents
    Patent number: 8772507
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 8, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Xiangping Qian, Andrew I. McDonald, Han-Jie Zhou, Luke W. Ashcraft, Bing Yao, Hong Jiang, Jennifer Kuo Chen Huang, Jianchao Wang, David J. Morgans, Jr., Bradley P. Morgan, Gustave Bergnes, Dashyant Dhanak, Steven D. Knight, Nicholas D. Adams, Cynthia A. Parrish, Kevin Duffy, Duke Fitch, Rosanna Tedesco
  • Certain chemical entities, compositions, and methods
    Patent number: 8759374
    Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: June 24, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Xiangping Qian, Chihyuan (Grace) Chuang, Pu-Ping Lu, Bing Yao, Qing (Kevin) Lu, Hong Jiang, Wenyue Wang, Bradley P. Morgan, David J. Morgans, Jr.
  • Certain chemical entities, compositions, and methods
    Patent number: 8653081
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: February 18, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley P. Morgan, Erica A. Kraynack, Pu-Ping Lu, Alex Muci, David J. Morgans
  • UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE
    Publication number: 20140038983
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 6, 2014
    Applicant: Cytokinetics, Incorporated
    Inventors: Bradley Paul MORGAN, Alex MUCI, Pu-Ping LU, Erica Anne KRAYNACK, Todd TOCHIMOTO, David J. MORGANS
  • Compounds, compositions and methods
    Patent number: 8633236
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: January 21, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Andrew McDonald, Gustave Bergnes, Bainian Feng, David J. Morgans, Jr., Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Christopher A. Brook
  • Heterocyclic sulfonamides
    Patent number: 8604025
    Abstract: Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 10, 2013
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley Paul Morgan, Fady Malik, Erica Anne Kraynack, Alexander Ramon Muci, Xiangping Qian, David J. Morgans, Jr.
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
    Publication number: 20130324549
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: May 17, 2013
    Publication date: December 5, 2013
    Applicant: Cytokinetics, Inc.
    Inventors: Bradley P. MORGAN, David J. Morgans, Alex Muci, Pu-Ping Lu, Erica A. Kraynack, Todd Tochimoto